Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 8/20 | 0.64 |
| ▸ | RAB9A | P51151 | 8/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | CASP3 | P42574 | 2/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.64 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | PKM | P14618 | 3/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | IGF1R | P08069 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | MECP2 | P51608 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7552432 | 0.83 | MEN1 (0.64) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5595819 | 0.82 | MAPT (0.55) | NPC1RAB9AMAPTKDM4E | |
| SCHEMBL4237969 | 0.82 | MAPT (0.67) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5595153 | 0.81 | RAB9A (0.58) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL8899001 | 0.81 | TP53 (0.60) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5595004 | 0.81 | MEN1 (0.68) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6763008 | 0.81 | CXCR2 (0.67) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11106394 | 0.80 | RAB9A (0.85) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL11092496 | 0.79 | RAB9A (1.00) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL29644384 | 0.78 | NPC1 (1.00) | POLBNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0809492-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-0896531-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020128321-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-6262113-B1 | HYDROXY- OR MERCAPTO-PHENYLUREAS | SMITHKLINE BEECHAM CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6211373-B1 | Phenyl urea antagonists of the IL-8 receptor | SMITHKLINE BEECHAM CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-6180675-B1 | THERAPY FOR CHEMOKINE SENSITIVE DISEASE; USING A AROMATIC (THIO)UREA COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2001-01-30 | — | — | US | disclosed |
| US-6005008-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-21 | — | — | US | disclosed |
| US-5886044-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0896531-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-17 | — | — | EP | disclosed |
| US-5780483-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0809492-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997029743-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996025157-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128321-A1 | IL-8 receptor antagonists | CXCL8, CCR8, IL1RN | POLB 4279/4885NPC1 1517/4885RAB9A 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.